Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download For Immediate Release…. VIVENTIA AND ESBATECH ENTER
Document related concepts
Transcript
For Immediate Release…. VIVENTIA AND ESBATECH ENTER COLLABORATION TO ENHANCE ANTIBODIES Toronto, Canada and Zurich, Switzerland, March 9th, 2004. - Viventia Biotech Inc. Toronto, Canada and ESBATech AG Zurich, Switzerland, announced today that they have entered into a license agreement and research collaboration. The goal of the collaboration is to investigate whether ESBATech’s unique antibody stabilization and expression technology can enhance the characteristics of certain antibodies discovered through Viventia’s proprietary antibody discovery and screening platforms Hybridomics™ and ImmunoMine™, with a view to the development of drug candidates in the field of oncology. Under the terms of the agreement ESBATech will receive an upfront payment and research funding. At the end of the collaboration, Viventia has the option to license the ESBATech technology for clinical development, with milestone payments and royalties due to ESBATech. As part of the research collaboration, ESBATech will utilize its proprietary technologies to investigate whether these technologies have the potential to enhance the stability, binding and yield of certain recombinant antibody fragments engineered by Viventia. Dr. Nick Glover, President and CEO, Viventia Biotech said, “Viventia seeks partners, such as ESBATech, who can complement our own discovery platforms and help us deliver on our goal of creating safer and more potent therapeutics for the fight against cancer. I look forward to a mutually beneficial collaboration with them.” ESBATech AG is a drug discovery and development company employing proprietary, fully human antibody fragment technology for the development of therapeutic applications in the fields of Alzheimer’s disease, respiratory infections and oncology. Dr. Dominik Escher, CEO, ESBATech commented, “ESBATech is very pleased with the recognition of the potential of its technology by Viventia. We are pleased to have the opportunity to work in collaboration with Viventia and look forward to helping Viventia advance its strategy of developing highly specific targeted therapeutics.” Viventia Biotech Inc. is developing innovative therapeutic products based upon the human immune response to cancer. Through its discovery platform, Hybridomics, target identification platform UnLock™, and its screening platform, ImmunoMine, the Company is focused on developing “Totally Human” monoclonal antibodies as Armed Antibodies™ to fight multiple forms of cancer. This press release contains forward-looking statements, which are subject to risks and uncertainties inherent to the process of developing and commercialising human therapeutic products. Actual results could differ materially from those projected in this release. The Toronto Stock Exchange has neither approved nor disapproved the information contained herein For additional information please contact: ESBATech AG Dr. Dominik Escher Chief Executive Officer Wagistr.21 CH-8952 Zurich-Schlieren Switzerland Tel: +41.1.733.4900 Fax: +41.1.733.4990 Email: [email protected] URL: www.esbastech.com Viventia Biotech Domenic LoParco Manager, Investor Relations 10 Four Seasons Place, Suite 501 Toronto, Ontario Canada M9B 6H7 Tel: +1.416.641.4585 Fax: +1.416.335.9306 Email: [email protected] URL: www.viventia.com
